A prospective, multi-center, observational clinical trial to assess the clinical effectiveness of gastric cancer prognostic prediction molecular diagnosis for patients with pathological stage ? and ? advanced gastric cancer

ovomics0 个研究点目标入组 688 人开始时间: 待定最近更新: 2023年4月4日

适应症

试验速览

暂无简介。

•1) Sample providers criteria
•? Male and female adult patients aged 19 years or over
•? Patients with histologically confirmed gastric adenocarcinoma
•? Patients with histologically confirmed stage ? or ?
•? Patients who have undergone radical gastrectomy
•? Patients who have not received neoadjuvant chemotherapy and radiotherapy
•? Patients who have undergone a radical gastrectomy and who show no evidence of residual tumors as observed with the unaided eye or through a microscope
•? Patients who have signed a written consent of the study and signed a human derived research agreement (Form 34)
•2) Sample criteria
•? The FFPE tumor specimens in storage have a tumor amount of at least 20% and therefore can be tested.
•? The quantity (not less than 400ng) and quality (A260/280 of not less than 1.8) of RNA are sufficient for analysis.

•1) Sample providers criteria
•? Male and female patients aged less than 19 years
•? Patients with histologically not confirmed gastric adenocarcinoma
•? Patients with histologically confirmed stage ? or ?
•? Patients who have not undergone radical gastrectomy
•? Patients who have received neoadjuvant chemotherapy or radiotherapy
•? Patients with distant or peritoneal metastasis at the time of surgery or residual tumors after surgery
•? Patients who have not signed the study's written consent and human derived research agreement (Form 34)
•2) Sample criteria
•? The FFPE tumor specimens in storage have a tumor amount of less than 20% and therefore cannot be tested
•? The quantity and quality of RNA are not sufficient for analysis

发起方

ovomics